RenovoRx Valuation
| RNXT Stock | USD 1.30 0.02 1.52% |
Today, the company appears to be undervalued. RenovoRx holds a recent Real Value of $2.3 per share. The prevailing price of the company is $1.3. Our model determines the value of RenovoRx from analyzing the company fundamentals such as Current Valuation of 33.98 M, return on equity of -1.36, and Shares Owned By Insiders of 4.40 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting RenovoRx's valuation include:
Price Book 3.6692 | Enterprise Value | Enterprise Value Ebitda (4.72) | Price Sales 198.0994 | Enterprise Value Revenue 141.5681 |
Undervalued
Today
Please note that RenovoRx's price fluctuation is risky at this time. Calculation of the real value of RenovoRx is based on 3 months time horizon. Increasing RenovoRx's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
RenovoRx's intrinsic value may or may not be the same as its current market price of 1.30, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.3 | Real 2.3 | Target 5.38 | Hype 1.28 | Naive 1.33 |
The intrinsic value of RenovoRx's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence RenovoRx's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of RenovoRx helps investors to forecast how RenovoRx stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of RenovoRx more accurately as focusing exclusively on RenovoRx's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use RenovoRx's intrinsic value based on its ongoing forecasts of RenovoRx's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against RenovoRx's closest peers.
RenovoRx Cash |
|
RenovoRx Valuation Trend
RenovoRx's real value is important for investors to make better decisions and a more accurate overall view of RenovoRx's financial worth over time. Using both RenovoRx's enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
RenovoRx Total Value Analysis
RenovoRx is at this time anticipated to have valuation of 33.98 M with market capitalization of 47.54 M, debt of 278 K, and cash on hands of 10.77 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the RenovoRx fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
33.98 M | 47.54 M | 278 K | 10.77 M |
RenovoRx Investor Information
About 28.0% of the company shares are owned by institutional investors. The book value of RenovoRx was at this time reported as 0.36. The company recorded a loss per share of 0.41. RenovoRx had not issued any dividends in recent years. Based on the key measurements obtained from RenovoRx's financial statements, RenovoRx is not in a good financial situation at this time. It has a very high odds of going through financial crisis in August.RenovoRx Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. RenovoRx has an asset utilization ratio of 0.53 percent. This implies that the Company is making $0.005297 for each dollar of assets. An increasing asset utilization means that RenovoRx is more efficient with each dollar of assets it utilizes for everyday operations.RenovoRx Ownership Allocation
RenovoRx owns a total of 36.57 Million outstanding shares. RenovoRx holds 4.4 pct. of its outstanding shares held by insiders and 27.55 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.RenovoRx Profitability Analysis
The company reported the previous year's revenue of 43 K. Net Loss for the year was (8.81 M) with profit before overhead, payroll, taxes, and interest of 146 K.About RenovoRx Valuation
The stock valuation mechanism determines RenovoRx's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of RenovoRx based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of RenovoRx. We calculate exposure to RenovoRx's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of RenovoRx's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 43 K | 45.1 K | |
| Pretax Profit Margin | (184.48) | (193.70) | |
| Operating Profit Margin | (229.60) | (241.08) | |
| Net Loss | (184.48) | (193.70) |
RenovoRx Growth Indicators
Investing in growth stocks can be very risky. If the company such as RenovoRx does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 23.6 M |
RenovoRx Current Valuation Indicators
RenovoRx's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final RenovoRx's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as RenovoRx, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use RenovoRx's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes RenovoRx's worth.Additional Tools for RenovoRx Stock Analysis
When running RenovoRx's price analysis, check to measure RenovoRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RenovoRx is operating at the current time. Most of RenovoRx's value examination focuses on studying past and present price action to predict the probability of RenovoRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RenovoRx's price. Additionally, you may evaluate how the addition of RenovoRx to your portfolios can decrease your overall portfolio volatility.